After Hours Summary: RUBI +19.2%, N +3.9%, MSFT +3%, TESS -15.6%, AMZN -10.7%, P -7.9% following earnings/guidance
After Hours Gainers:
Companies trading higher in after hours in reaction to earnings: RUBI +19.2%, KLAC +15.1%, GIMO +14.3%, BJRI +13%, QLIK +9.8%, MXWL +7.8%, GHL +4.4%, FII +4%, N +3.9%, PFPT +3.6%, SPNC +3.4%, MSFT +3%, RMD +2.7%, SWFT +2%, CB +2%, IM +1.8%, PACB +1.8%, LOGM +0.9%, POL +0.6%, RVBD +0.4%, JNPR +0.4%, PAC +0.3%, DLB +0.2%
Companies trading higher in after hours in reaction to news: VTAE +38.6% (announced positive top-line results from clinical trials in treatment and prevention of Alzheimer's disease as part of the collaboration with Boehringer Ingelheim), RP +13.4% (seeing reports that multiple buyers are interested in the company), MXWL +7.8% (announced development agreement with Corning (GLW) to advance Ultracapacitor technologies), EMES +4.2% (declared a cash distribution of $1.38 for the third quarter of 2014, an 18% increase over the second quarter 2014 distribution of $1.17 per unit), PFPT +3.6% (signed a definitive agreement to acquire Nexgate for $35 mln in cash), LJPC +1.9% (announced short term therapy with the galectin-3 inhibitor, GCS-100 at 1.5 mg/m2, resulted in small but significant improvement in eGFR)
After Hours Losers:
Companies trading lower in after hours in reaction to earnings: TESS -15.6%, LAYN -14.3%, SYNA -12.7%, AMZN -10.7%, UFCS -8.5%, P -7.9%, OLN -7.6%, FLS -6.6%, MXIM -5.8%, FSL -5.8%, LSCC -5.6%, ALTR -3.7%, FWRD -3.3%, VMI -3.1%, JBSS -3%, CLNE -2.7%, DECK -2.4%, ELY -2.1%, CERN -2.1%, INFA -1.8%, NCR -1.4%, BMRN -1.4%, WIRE -1.2%, ALGN -1.1%, CPWR -0.9%, VRSN -0.6%, NTGR -0.1%
Companies trading lower in after hours in reaction to news: SUTR -19.1% (disclosed that Board approved of dismissal of Grant Thornton, the China member firm of Grant Thornton International, as the company's independent registered public accounting firm), DRYS -16.5% (announced offering of common stock), NPSP -7.2% (announced that the PDUFA action date for the Natpara BLA was extended three months to January 24, 2015), ABG -5.4% (appointed David Hult Chief Operating Officer; Michael Kearney to retire in March 2015), GEVA -1.4% (presented sebelipase alfa data for LAL Deficiency: six infants met the primary endpoint of survival at 12 months of age and five infants continue on treatment with sebelipase alfa)